Sign In
Buy AMLX
$13.20
-0.0900 (-0.677%)
At Close: Jun 03, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
04:32pm, Tuesday, 03'rd Mar 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
07:00am, Tuesday, 03'rd Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the fourth quarter and full year en
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
09:00am, Thursday, 26'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences.
Financial Survey: Amylyx Pharmaceuticals (NASDAQ:AMLX) vs. Theravance Biopharma (NASDAQ:TBPH)
01:15am, Tuesday, 10'th Feb 2026
Theravance Biopharma (NASDAQ: TBPH - Get Free Report) and Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will comp
Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million
11:49pm, Saturday, 31'st Jan 2026
Joshua B Cohen sold 138,167 shares for a total transaction value of ~$1.9 million on Jan. 15 and Jan. 16, 2026, at a weighted average price of $13.59 per share. This sale represented 3.93% of Cohen's
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
05:05pm, Thursday, 29'th Jan 2026
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?
07:00am, Tuesday, 09'th Dec 2025
Austin-based Saturn V Capital Management added 1.3 million shares of Amylyx Pharmaceuticals in the third quarter. The overall position increased in value by $41.2 million from quarter to quarter.
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
09:00am, Friday, 05'th Dec 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
07:53pm, Wednesday, 03'rd Dec 2025
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?
09:45am, Wednesday, 03'rd Dec 2025
New York City-based Commodore Capital bought nearly 4.1 million shares, increasing portfolio value by an estimated $55 million. The position represents 2.7% of 13F reportable assets under management (
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
06:40pm, Friday, 28'th Nov 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Nov. 28, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inve
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead
12:20pm, Monday, 17'th Nov 2025
California-based TCG Crossover bought 300,000 shares of Amylyx Pharmaceuticals for an estimated $46.8 million in the third quarter. At quarter-end, TCG Crossover reported holding 6.2 million total sha
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceutica
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceutica
